Equities

Regent Pacific Group Ltd

Regent Pacific Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.40
  • Today's Change0.01 / 2.56%
  • Shares traded100.00
  • 1 Year change-59.60%
  • Beta1.1113
Data delayed at least 15 minutes, as of Sep 20 2024 08:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2.421.4411
Total Receivables, Net0.040.010
Total Inventory------
Prepaid expenses0.300.860.46
Other current assets, total0.0301.20
Total current assets2.792.3113
Property, plant & equipment, net0.010.300.78
Goodwill, net----0
Intangibles, net02449
Long term investments00.000.00
Note receivable - long term------
Other long term assets------
Total assets2.802662
LIABILITIES
Accounts payable0.100.080.22
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.43146.43
Other current liabilities, total3.054.534.28
Total current liabilities3.581811
Total long term debt0.770.027.58
Total debt1.201414
Deferred income tax05.394.95
Minority interest----0
Other liabilities, total------
Total liabilities4.352423
SHAREHOLDERS EQUITY
Common stock0.232424
Additional paid-in capital294294292
Retained earnings (accumulated deficit)(297)(318)(280)
Treasury stock - common------
Unrealized gain (loss)(1.5)(1.5)(1.5)
Other equity, total3.343.544.61
Total equity(1.55)2.6039
Total liabilities & shareholders' equity2.802662
Total common shares outstanding228120120
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.